SwedenSweden

300 Participants at Biotech Days

10.07.2004

More than 300 participants attended the Biotech Days in Gothenburg arranged by SwedenBIO at its annual meeting. Gothenburg is one of the most expansive biotech regions in Scandinavia and hosts a major R&D center for AstraZeneca. During the past 18 months, SwedenBIO has grown rapidly and has today 75 member companies. Discussions are under way to open up a branch for advanced Med-Tech companies following an interest from leading companies like Gambro AB and Elekta AB. Med-Tech companies share many challenges with biotechs, such as the availability to seed and bridge capital, and to keep up excellence in research and demanding regulatory requirements.

“We have expanded our membership base from seven founders to 75 member companies within the last year. We are happy for the strong support from the industry leaders, which has enabled us to establish SwedenBIO as the voice of the biotech industry. The recognition by leading Med-Tech executives is promising, allowing us to have a coherent approach towards our government and other stakeholders as well as giving critical mass,” says Dr. Hans Nyctelius, CEO of SwedenBIO. The organization, whose objective it is to improve the industrial environment for biotech in Sweden, launched an action plan “A National Biotech Agenda for Growth” in February proposing 18 governmental actions to secure Sweden's leading position. “We have very good discussions with our government and we expect to have a National Biotech Committee in place in Q3,” says Nyctelius.
The Biotech Days hosted a seminar “Future Trends in Biotechnology” where panels on current stem cell research were followed by a speech of Dr. Martin Nicklasson, Executive VP Global Drug Development at AstraZeneca, on their outlook for big pharma. He expressed a strong need for bio-techs and big pharma to collaborate more as well as for a pro-active stance of the Swedish government to allow Astra-Zeneca to strengthen its presence in Sweden. The leading academic IP center in Scandinavia, the Center for Intellectual Property Studies at Chalmers University provided the venue for the seminar “Biotech IP Focus '04”. More than 180 international participants discussed the strategic management of intellectual property rights in biotechnology and how to create value from IP in R&D development and business. Keynote speakers included Robert Blackburn, Head of Legal at Chiron Corp., and Peter de Weerd, Global Head of Patents at Novartis Pharma. SwedenBIO will continue to arrange top-level seminars addressing critical business topics. A Swedish-US biotech day is scheduled for September 9, 2004 in Stockholm.

Contact
Dr. Hans Nyctelius, CEO SwedenBIO
eMail: info@swedenbio.com

SwedenSweden

12.03.2012

Gothenburg – Researchers at the Sahlgrenska Academy have discovered a previously unknown mechanism which helps intestinal bacteria to affect the formation of blood vessels. In a study of mice, the team led by Fredrik Bäckhed...

SwedenSweden

08.03.2012

Swiss Nestlé S.A. has extended its collaboration agreement with BioGaia AB. The world’s largest nutrition company is paying up to €50.8m for a perpetual licence to use BioGaia’s patented Lacto­bacillus reuteri in infant nutrition...

SwedenSweden

08.03.2012

Stockholm – Swedish drug delivery specialist Orexo AB has announced the intention to cut its headcount by 30% in order to reduce the company's burn rate. The personnel reduction by 35 people is expected to lower the costs by a...

SwedenSweden

07.03.2012

After a long period of negotiations, Sweden’s Orexo AB and Belgium’s Janssen Pharmaceutica have terminated their joint research programmes. “Unfortunately, we lack the funds to continue on our own to develop the OX-CLI and OX-ESI...

SwedenSweden

06.03.2012

Uppsala/Moscow – Vaccine adjuvant specialist Isconova AB is set to begin receiving royalties and product revenues from Russian partner VetBioChem. The veterinary medicine company has launched two new rabies vaccines for dogs and...

SwedenSweden

23.02.2012

Stockholm - Probiotics can help prevent diseases, Swedish researchers have found out. The results are in sharp contrast with all health claim judgements involving probiotics published by the EU's food watchdog EFSA up to now. The...

SwedenSweden

16.02.2012

Huddinge – Full stop for one of Sweden's most promising biotech companies. Karo Bio has terminated the trial of its late-stage cholesterol drug eprotirome and won't proceed with its plans to spin off its preclinical operations....

SwedenSweden

19.12.2011

Helsingborg/Exton – Swedish drug developer DuoCort Pharma AB has been purchased by US-based biopharmaceuticals maker ViroPharma Inc. ViroPharma paid around €25m up front, but DuoCort’s former owners could end up receiving €97m...

SwedenSweden

15.12.2011

Stockholm/Cologne – Researchers at the Swedish Karolinska Institute and the University of Cologne have identified a new protein-based defense mechanism against cancer (Struct. & Molec. Biology, doi: 10.1038/10.1038/nsmb.2188)....

SwedenSweden

15.12.2011

Craigavon/Uppsala – Irish Almac Discovery, a member of the Almac Group, will begin cooperating with Uppsala-based Beactica AB to develop new cancer drug candidates. In late November, the companies announced that Beactica’s Sprint...

Displaying results 1 to 10 out of 182

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-sweden/article/300-participants-at-biotech-days.html

Stock list

All quotes

TOP

  • SERODUS (N)3.05 NOK7.02%
  • SUMMIT (UK)4.03 GBP3.87%
  • DEINOVE (F)13.32 EUR2.46%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • ALMIRALL (E)11.07 EUR-7.13%

TOP

  • SANTHERA (CH)70.65 CHF114.1%
  • CELLECTIS (F)13.54 EUR112.6%
  • ADDEX (CH)4.54 CHF108.3%

FLOP

  • THROMBOGENICS (B)8.51 EUR-51.5%
  • MERCK KGAA (D)63.67 EUR-50.6%
  • VERONA PHARMA (UK)1.20 GBP-42.9%

TOP

  • SANTHERA (CH)70.65 CHF3111.4%
  • GW PHARMACEUTICALS (UK)443.50 GBP843.6%
  • PAION (D)2.71 EUR310.6%

FLOP

  • CYTOS (CH)0.24 CHF-93.1%
  • EVOCUTIS (UK)0.21 GBP-92.6%
  • THROMBOGENICS (B)8.51 EUR-73.6%

No liability assumed, Date: 12.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events